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Abstract
AIM: To investigate the presence of mixed infection 
and discrepancy between hepatitis C virus (HCV) geno­
types in plasma, peripheral blood mononuclear cells 
(PBMCs), and liver biopsy specimens.
METHODS: From September 2008 up to April 2009, 
133 patients with chronic hepatitis C referred to Fir­
ouzgar Hospital for initiation of an antiviral therapy were 
recruited in the study. Five milliliters of peripheral blood 
was collected from each patient and liver biopsy was 
performed in those who gave consent or had indica­
tions. HCV genotyping was done using INNO-LiPA™ 
HCV Ⅱ in serum, PBMCs, and liver biopsy specimens 
and then confirmed by sequencing of 5’-UTR fragments.
RESULTS: The mean age of patients was 30.3 ± 17.1 
years. Multiple transfusion was seen in 124 (93.2%) of 
patients. Multiple HCV genotypes were found in 3 (2.3%) 
of 133 plasma samples, 9 (6.8%) of 133 PBMC samples, 
and 8 (18.2%) of 44 liver biopsy specimens. It is no­
table that the different genotypes found in PBMCs were 
not the same as those found in plasma and liver biopsy 
specimens. 
CONCLUSION: Our study shows that a significant pro­
portion of patients with chronic hepatitis C are affected 
by multiple HCV genotypes which may not be detect­
able only in serum of patients. 
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Hepatitis C virus (HCV) is an enveloped positive-stranded 
RNA virus of  the family Flaviviridae and genus Hepacivi-
rus that causes both acute and chronic hepatitis[1-3]. HCV 
is a major health problem affecting 170 million people 
worldwide[4]. It is estimated that chronic HCV infection is 
responsible for approximately 250 000 to 350 000 deaths 
per year, mainly related to decompensation of  cirrhosis, 
end-stage liver disease, and hepatocellular carcinoma[5]. 
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Phylogenetic analysis of  HCV sequences resulted in 
a nomenclature that recognizes distinct virus types and 
subtypes[6]. Six large groups of  viral genotypes[7-12], in ad-
dition to over 70 different subtypes (termed a, b, c, etc.) are 
distributed worldwide[6,13]. The HCV genotypes should be 
systematically determined before treatment, as it deter-
mines the indication, the duration of  treatment, the dose 
of  ribavirin and the virological monitoring procedure[14].
The HCV is considered as essentially hepatotropic[15], 
but virus sequences have also been found in other impor-
tant extrahepatic sites, including peripheral blood mono-
nuclear cells (PBMCs), the central nervous system, and 
bone marrow from chronically-infected patients[16-19].
HCV replicates through a negative-strand interme-
diary. Although hepatocytes are the primary sites for HCV 
replication, there is evidence of  negative-strand HCV 
RNA in PBMCs. The HCV genomic sequences present 
in PBMCs have been found to differ from those found in 
serum and the liver biopsy specimens[20-24]. Detection of  
HCV RNA in extrahepatic reservoirs has important impli-
cations for transmission, disease progression, and effective 
treatment[25]. Furthermore, the PBMC compartment may 
be a privileged site for HCV, which is able to reinitiate vi-
ral replication after termination of  HCV treatment when 
conditions again become more favorable. Re-infection of  
HCV after orthotropic liver transplantation has postulated 
that extrahepatic sites are suitable for HCV replication[26]. 
Thus, even if  clearance of  HCV from hepatocytes is 
achieved by treatment, re-infection from extrahepatic sites, 
such as the PBMC compartment, may occur[27].
The purpose of  the present study is to determine the 
presence and frequency of  different HCV genotypes in 




In this cross-sectional study, 133 consecutive patients 
with established chronic hepatitis C referred to Firouzgar 
Hospital from September 2008 to July 2009 were enrolled. 
Informed consents were obtained from the patients, and 
the study was approved by the local ethics committee of  
GI and Liver Disease Research centre (GILDRC) of  Iran 
University of  Medical Sciences. 
Inclusion criteria were positive anti-HCV antibodies 
along with positive plasma HCV RNA. Also none of  the 
included patients had been treated for HCV previously. 
Collection and preparation of samples
About 5 mL of  peripheral blood were collected from each 
patient into EDTA-containing vacutainer tubes. Plasma 
was stored at -70℃ until analysis. PBMCs were isolated 
from EDTA-treated blood by centrifugation over density 
gradient (Lymphoprep, Oslo, Norway). PBMCs were then 
washed three times with phosphate-buffered saline (pH = 
7.4), counted and stored at -70℃ for later detection. Some 
of  the patients who gave consent underwent a liver biopsy 
for diagnostic purpose. Liver biopsy specimens were di-
vided into 2 portions: one used for histological diagnosis, 
and the second was submerged into RNALater (Ambion 
Inc., Austin, TX) and stored at -70℃ for HCV genotyp-
ing. Samples of  serum and PBMCs were collected from all 
patients on the same day the liver biopsy was performed.
Isolation of RNA from serum, PBMCs, and liver
RNA was extracted from 140 µL of  plasma by using 
the QIAamp Viral RNA Extraction kit (Qiagen GmbH, 
Hilden, Germany), from a pellet of  approximately 3-5 
× 106 PBMCs using the RNA Virus Mini Extraction Kit 
(Invitek GmbH, Germany), and from approximately 
2 mm3 of  liver biopsy specimens using the DNA/RNA 
Virus Mini Extraction Kit (Invitek GmbH, Germany), 
according to the manufacturer’s instructions.
HCV genotyping 
RNA was isolated from plasma, PBMC, and liver biopsy 
specimens as described above. 5’-untranslated region (5’- 
UTR) genotyping was done using a standard methodol-
ogy with the INNO-LiPA™ HCV Ⅱ kit (Innogenetics, 
Ghent, Belgium) according to the manufacturer’s instruc-
tions. Briefly, the 5’-UTR is amplified with biotinylated 
primers. Biotin-labeled PCR products are reverse hybrid-
ized to specific probes attached to nitrocellulose strips and 
then incubated with a chromogen. Developing results in a 
purple precipitate that forms a line on the strip. The HCV 
type is deduced on the basis of  the patterns of  hybridizing 
bands, using the line probe assay interpretation chart[28].
INNO-LiPA™ HCV Ⅱ genotyping has also been con-
firmed by sequencing of  5’-UTR fragments. The HCV 5’- 
UTR was amplified from total RNA isolated from plasma, 
PBMC, and liver biopsy specimens of  10 randomly se-
lected patients by reverse transcriptase-PCR as described 
previously[29]. The 211-bp 5’-UTR PCR products were 
sequenced by dye termination method using the ABI 3130 
XL sequencer. The sequencing results were compared with 
other sequences posited in gene bank by Blast software.
Statistical analysis
Data analysis was done by SPSS software version 16.0, 
using descriptive statistical indexes such as mean and stan-
dard deviation (SD), 95% confidence interval (CI) and t 
test. P value less than 0.05 was considered statistically sig-
nificant.
RESULTS
One hundred and thirty three patients with established 
chronic hepatitis C were recruited in this study. Multiple 
blood transfusion was the most important related risk 
factor found in 124 (93.2%) of  patients, 87 (65.4%) with 
thalassemia and 37 (27.8%) with hemophilia. The source 
of  infection was unknown in 9 (6.8%) patients. The mean 
age of  patients was 30.3 ± 17.1 years. Out of  133 patients, 
100 (75.2%) were male. The mean viral load of  all of  the 
patients was 6.3 × 105 ± 7.8 × 105 (range from 45 000 to 
5.59 × 106). Out of  133 patients, 44 patients gave consent 
to undergo liver biopsy. Genotype 1a was the most fre-
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quent genotype in serum (63.9%), PBMCs (61.0%), and in 
liver biopsy specimens (54.5%). HCV genotypes in serum, 
PBMCs, and liver biopsy specimens of  all patients were 
similar except for 20 patients (15%). 
The complete data of  these patients have been sum-
marized in Table 1. As shown in Table 2, more than one 
HCV genotype has been found in some patients, as 3 (2.3%) 
patients had different HCV genotypes in their serum sam-
ples. In 9 (6.8%) patients, different HCV genotypes were 
found in PBMCs. In 8 (18.2%) patients (who were not ex-
actly same as the 9 patients with different HCV genotypes 
in PBMCs) multiple HCV genotypes were found in liver bi-
opsy specimens. The INNO-LiPA™ HCV Ⅱ genotyping 
was confirmed with sequencing of  the 5’-UTR. A 100% 
correlation was demonstrated between INNO-LiPA™ 
HCV Ⅱ genotyping and sequencing of  the 5’-UTR.
DISCUSSION
The present study was performed on 133 chronically 
HCV infected patients to evaluate the prevalence of  po-
tential mixed HCV infection in their plasma, PBMCs, and 
liver biopsy specimens. In 15% of  these patients different 
HCV genotypes were found in these compartments. Mul-
tiple HCV genotypes were detected in 3 (2.3%) of  133 
plasma, 9 (6.8%) of  133 PBMC, and 8 (18.2%) of  44 liver 
biopsy specimens.
Mixed infection is infection of  an individual with two 
or more distinct HCV genotypes. Mixed viral infection is 
of  great clinical importance as it may result in more severe 
disease, unresponsiveness to antiviral therapy or recur-
rence after the completion of  antiviral therapy course[30].
In our study, various HCV genotypes presented in 
PBMCs were different from those found in plasma or 
liver biopsy specimens (Table 1). It means that PBMCs 
may present some divergent types, which are not detect-
able in liver biopsy specimens. It reinforces the previous 
proposed theories in which PBMCs have been known as 
an extrahepatic replication site for HCV[17,25,26,31-34].
It is suggested that infection with one HCV type doesn’t 
make a barrier to acquisition of  other genotypes, therefore 
multiple exposures to HCV especially in potential risk 
groups, might lead to several episodes of  re-infection and 
to the establishment of  mixed infection in some patients. 
It is also well known that super infection with a new HCV 
strain leads to suppression of  one virus under the detec-
tion limit of  PCR while the other one prevails as under 
antiviral therapy, the displaced strain may become viremic 
again and may alter the outcome of  therapy[30,35-39]. 
In our study the prevalence of  mixed HCV infection 
was estimated about 2.3% in plasma, 6.8% in PBMC, and 
18.2% in liver biopsy specimens of  chronically infected 
patients with HCV. Mixed infection with two HCV geno-
types have been detected in 1% of  HCV-positive patients, 
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Table 1  Distribution of different HCV genotypes in plasma, PBMCs, and liver biopsy specimens




HCV genotypes in liver 
biopsy specimen
1 F/15 76 500 Thalassemia 3 3/1a 3
2 F/36 138 000 Thalassemia 1a 3 1a
3 M/17 597 000 Hemophilia 1a/3 1a
4 M/23 989 000 Thalassemia 1a/1b 1b 1a/1b/3
5 M/23 226 000 Thalassemia 1a/1b 1b 1a/1b
6 M/33 450 Thalassemia 1a 3
7 M/26 250 000 Thalassemia 3 1a 1a/3
8 M/17 106 000 Thalassemia 1a 1a/3
9 M/25 780 000 Thalassemia 1a 1a 1a/3
10 F/30 10 800 Thalassemia 1b 1a/1b 1b/3
11 F/27 750 000 Thalassemia 3 3 3/1b
12 M/14 5 590 000 Thalassemia 3 3 1a/3
13 M/28 1 190 000 Thalassemia 1a 1a/3 1a
14 M/19 1 150 000 Hemophilia 1a 1a/3
15 M/20 890 000 Thalassemia 1a 1a/1b
16 F/22 618 000 Thalassemia 3 3 3/2a
17 M/27 167 000 Thalassemia 3 3/2a
18 M/46 230 000 Hemophilia 3 3/2a
19 M/27 273 000  Hemophilia 3 3/2a
20 M/57 480 000 Unknown 4 3
HCV: Hepatitis C virus; PBMCs: Peripheral blood mononuclear cells.
Table 2  Frequency of HCV genotypes in plasma, PBMCs, 
and liver biopsy specimens  n  (%)





in liver biopsy 
specimen
1a 85 (63.9)   81 (61.0) 24 (54.5)
1b 8 (6.0) 10 (7.5) 3 (6.8)
2 0 (0.0)   0 (0.0) 0 (0.0)
3 35 (26.2)   33 (24.8)   9 (20.0)
4 2 (2.3)   1 (0.8) 0 (0.0)
Mixed infection 3 (2.3)   9 (6.8)   8 (18.2)
Total 133 133 44
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using type-specific primers[40,41]. Also figures of  1.6% to 
31% have been reported in multi-transfused hemophili-
acs[42,43].
Our study demonstrated that a significant proportion 
of  HCV infected patients have divergent HCV genotypes 
in their PBMCs and liver biopsy specimens which were 
not detectable in their plasma. 
In the present study we used INNO-LiPA™ HCV Ⅱ 
genotyping which is currently the most applied method 
and has more sensitivity than RFLP. One of  the prob-
lems of  INNO-LiPA™ HCV Ⅱ is that it may underesti-
mate the actual rate of  mixed infection[9,30,44]. According 
to this, the true prevalence of  mixed infection may be 
higher than estimated in this study.
The second shortcoming is that only 44 of  our pa-
tients had indication or gave consent to undergo liver 
biopsy, however, 18.2% of  them had multiple HCV geno-
types which is a significant proportion of  the total. It in-
dicates that hepatocytes are the main reservoirs for HCV. 
On the other hand since performance of  liver biopsy is 
not possible for all patients, we suggest the assessment of  
PBMCs as another HCV reservoir for detection of  HCV 
mixed infection[26,34,45]. 
In conclusion, our study shows that patients with hemo-
philia and thalassemia are from the most high risk groups 
in whom mixed infection is relatively common. On the 
other hand failure to treatment and relapse of  infection is 
also frequent in these groups. So it seems that considering 
the plasma genotype as the target genotype for schedul-
ing of  an anti HCV therapy may be one of  the factors 
that leads to the failure of  treatment. HCV genotyping in 
PBMCs or liver biopsy specimens might be beneficial.
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